Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 29, 2016

Primary Completion Date

January 23, 2024

Study Completion Date

January 23, 2024

Conditions

Myelofibrosis

Interventions

OTHER

Long-term Follow-up

Undergo follow-up assessment

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

Ruxolitinib

Given PO

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02784496 - Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis | Biotech Hunter | Biotech Hunter